Ratios

		vs industry	vs history
P/E(ttm)	20.90	MYGN's P/E(ttm) is ranked higher than 78% of the 90 Companies in the Global Diagnostics & Research industry. ( Industry Median: 20.95 vs. MYGN: 20.90 )	MYGN' s 10-Year P/E(ttm) Range Min: 9.42   Max: 63.14 Current: 20.9 9.42 63.14
P/S	4.84	MYGN's P/S is ranked lower than 70% of the 90 Companies in the Global Diagnostics & Research industry. ( Industry Median: 2.22 vs. MYGN: 4.84 )	MYGN' s 10-Year P/S Range Min: 3.4   Max: 67.68 Current: 4.84 3.4 67.68
PFCF	26.34	MYGN's PFCF is ranked higher than 70% of the 90 Companies in the Global Diagnostics & Research industry. ( Industry Median: 19.30 vs. MYGN: 26.34 )	MYGN' s 10-Year PFCF Range Min: 9.3   Max: 433.47 Current: 26.34 9.3 433.47
EV-to-EBIT	11	MYGN's EV-to-EBIT is ranked higher than 92% of the 90 Companies in the Global Diagnostics & Research industry. ( Industry Median: 17.90 vs. MYGN: 11 )	MYGN' s 10-Year EV-to-EBIT Range Min: 7.5   Max: 84.8 Current: 11 7.5 84.8
PEG	1.24	MYGN's PEG is ranked lower than 67% of the 90 Companies in the Global Diagnostics & Research industry. ( Industry Median: 1.90 vs. MYGN: 1.24 )	MYGN' s 10-Year PEG Range Min: 0.52   Max: 0.7 Current: 1.24 0.52 0.7
Shiller P/E	29.13	MYGN's Shiller P/E is ranked higher than 69% of the 90 Companies in the Global Diagnostics & Research industry. ( Industry Median: 12.19 vs. MYGN: 29.13 )	MYGN' s 10-Year Shiller P/E Range Min: 21.68   Max: 359 Current: 29.13 21.68 359

Valuation & Return

		vs industry	vs history
Price/DCF (Projected)	1.3	MYGN's Price/DCF (Projected) is ranked higher than 77% of the 90 Companies in the Global Diagnostics & Research industry. ( Industry Median: 1.30 vs. MYGN: 1.3 )	MYGN' s 10-Year Price/DCF (Projected) Range Min: 1.1   Max: 27.1 Current: 1.3 1.1 27.1
Price/Median PS Value	0.7	MYGN's Price/Median PS Value is ranked higher than 50% of the 90 Companies in the Global Diagnostics & Research industry. ( Industry Median: 0.90 vs. MYGN: 0.7 )	MYGN' s 10-Year Price/Median PS Value Range Min: 0.5   Max: 5.6 Current: 0.7 0.5 5.6
Earnings Yield (Greenblatt)	9.10	MYGN's Earnings Yield (Greenblatt) is ranked higher than 92% of the 90 Companies in the Global Diagnostics & Research industry. ( Industry Median: 5.60 vs. MYGN: 9.10 )	MYGN' s 10-Year Earnings Yield (Greenblatt) Range Min: 1.2   Max: 13.3 Current: 9.1 1.2 13.3
Forward Rate of Return (Yacktman)	33.16	MYGN's Forward Rate of Return (Yacktman) is ranked higher than 91% of the 90 Companies in the Global Diagnostics & Research industry. ( Industry Median: 0.46 vs. MYGN: 33.16 )	MYGN' s 10-Year Forward Rate of Return (Yacktman) Range Min: -2.7   Max: 35 Current: 33.16 -2.7 35

Business Description

Myriad Genetics, Inc., is a Delaware corporation. The Company is molecular diagnostic company dedicated to making a difference in patients' lives through the discovery and commercialization of transformative tests which assess a person's risk of developing disease, guide treatment decisions and assess risk of disease progression and recurrence. It performs all of its molecular diagnostic testing and analysis in its own reference laboratories and employs a number of proprietary technologies that help it understand the genetic basis of human disease and the role that genes and their related proteins may play in the onset and progression of disease. These technologies include the cornerstone technologies of biomarker discovery, high-throughput DNA sequencing, RNA expression and multiplex protein analysis. It use this information to guide the development of new molecular diagnostic tests that are designed to assess an individual's risk for developing disease later in life (predictive medicine), identify a patient's likelihood of responding to drug therapy and guide a patient's dosing to ensure optimal treatment (personalized medicine), or assess a patient's risk of disease progression and disease recurrence (prognostic medicine). To date, it has launched nine commercial molecular diagnostic tests. It markets these tests through its own approximate 385-person sales force in the United States. It also market its BRACAnalysis, COLARIS, and COLARIS AP tests through its own European sales force and has entered into marketing collaborations with other organizations in selected Latin American, European and Asian countries. It also generates revenue by providing companion diagnostic services to the pharmaceutical, and biotechnology industries and medical research institutions utilizing its multiplexed immunoassay technology. Its competitors in the United States and abroad are numerous and include other molecular diagnostic companies, diagnostic reference laboratories, large multi-national healthcare companies, and universities and other research institutions. The services that the Company provides are heavily regulated by federal, state and foreign governmental authorities.
Company Website
SEC Reports

Industry:	Diagnostics & Research
Compare:	LH, ALR, DGX, LIFE, ENZ
Traded in other countries:	MYD.Germany

» More Articles for MYGN

Headlines

Articles On GuruFocus.com

Royce Fund's Chip Skinner on the Rebound of Royce Value Plus Fund and Stock Ideas Dec 04 2012

RS Investments' Value Fund First Quarter 2012 Mutual Fund Commentary Apr 17 2012

Chuck Royce Buys Hawkins Inc., Myriad Genetics, and Fairchild Semiconductor Jul 07 2011

New Magic Formula Stocks from Joel Greenblatt: Q1 Portfolio May 17 2011

Myriad Genetics Inc. Reports Operating Results (10-Q) May 05 2010

Myriad Genetics Inc. (MYGN) CFO James S Evans sells 8,400 Shares Mar 12 2010

Guru Stocks at 52-Week Low: Nasdaq, Dun & Bradstreet Corp, GameStop Corp, Dean Foods Company, Myriad Feb 15 2010

Myriad Genetics Inc. Reports Operating Results (10-Q) Feb 03 2010

Guru Stocks at 52-Week Low: GameStop Corp, Myriad Genetics Inc, MetroPCS Communications Inc, Emdeon Jan 24 2010

Myriad Genetics Inc. Reports Operating Results (10-Q) Nov 04 2009

Personalized Checklist